These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 17573688)

  • 21. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.
    Willan A; Kowgier M
    Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A parallel phase I/II clinical trial design for combination therapies.
    Huang X; Biswas S; Oki Y; Issa JP; Berry DA
    Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials.
    Jin H; Wei Z
    Contemp Clin Trials; 2012 Nov; 33(6):1255-60. PubMed ID: 22772088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative designs of phase II trials considering response and toxicity.
    Jin H
    Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curtailed two-stage designs in Phase II clinical trials.
    Chi Y; Chen CM
    Stat Med; 2008 Dec; 27(29):6175-89. PubMed ID: 18816510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On group sequential designs comparing two binomial proportions.
    Kepner JL
    J Biopharm Stat; 2010 Jan; 20(1):145-59. PubMed ID: 20077254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II clinical trials.
    Jung SH; Sargent DJ
    J Biopharm Stat; 2014; 24(4):802-16. PubMed ID: 24697589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporating toxicity considerations into the design of two-stage phase II clinical trials.
    Bryant J; Day R
    Biometrics; 1995 Dec; 51(4):1372-83. PubMed ID: 8589229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-stage designs for phase II cancer trials with ordinal responses.
    Stallard N; Cockey L
    Contemp Clin Trials; 2008 Nov; 29(6):896-904. PubMed ID: 18703164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A three-outcome design for randomized comparative phase II clinical trials.
    Hong S; Wang Y
    Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designs for randomized phase II clinical trials with two treatment arms.
    Hou W; Chang MN; Jung SH; Li Y
    Stat Med; 2013 Nov; 32(25):4367-79. PubMed ID: 23630064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
    Shan G; Zhang H; Jiang T
    BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An exact method for analysis following a two-stage phase II cancer clinical trial.
    Jovic G; Whitehead J
    Stat Med; 2010 Dec; 29(30):3118-25. PubMed ID: 21170906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential designs for phase III clinical trials incorporating treatment selection.
    Stallard N; Todd S
    Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting population entering phase III trials: a new stratified adaptive phase II design.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.